MCM
UTHR icon

Massar Capital Management’s United Therapeutics UTHR Stock Holding History

Massar Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.36M Buy
+8,055
New +$4.54M 0.42% 29
2025
Q1 		– Sell
-13,126
Closed -$4.63M – 156
2024
Q4 		$4.63M Buy
+13,126
New +$4.82M 5.27% 4

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Massar Capital Management's UTHR Position: Q2 2026 in Review

Massar Capital Management opened a new position in United Therapeutics (UTHR) in Q2 2026: 8,055 shares worth $4.36M. The stake represents 0.42% of the portfolio and ranks #29 among its holdings. This is a return to the name: Massar Capital Management previously reported a position in UTHR as recently as Q4 2024.

Massar Capital Management first reported a position in UTHR in Q4 2024 and has held it in 2 quarters since. The position peaked at $4.63M in Q4 2024. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Massar Capital Management held 8,055 shares of United Therapeutics worth $4.36M as of Q2 2026.
  • United Therapeutics was a new Massar Capital Management position in Q2 2026.
  • United Therapeutics made up 0.42% of Massar Capital Management's portfolio in Q2 2026, its #29 holding.
  • Massar Capital Management first reported a position in United Therapeutics in Q4 2024 and has held it in 2 quarters since.
  • Massar Capital Management's United Therapeutics position peaked at $4.63M in Q4 2024.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Massar Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.